Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

ERAXIS

ANIDULAFUNGIN

Standard Dose
50MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ERAXIS is listed in Drugs@FDA under application 021632 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ANIDULAFUNGIN Form and strength POWDER;INTRAVENOUS - 50MG/VIAL Sponsor VICURON HOLDINGS Submission history Latest submission status date: 2020-10-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview ERAXIS is listed in Drugs@FDA under application 021632 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ANIDULAFUNGIN Form and strength POWDER;INTRAVENOUS - 50MG/VIAL Sponsor VICURON HOLDINGS Submission history Latest submission status date: 2020-10-05 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ERAXIS (ANIDULAFUNGIN) | Drug Monograph | MedicHelpline